Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Jubilant Pharmova's Revenue for the
three
months ended in Jun. 2026 was ₹22,211 Mil. Jubilant Pharmova's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹10,696 Mil.
Hence, Jubilant Pharmova's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.08.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Jubilant Pharmova Receivables Turnover Related Terms
Jubilant Pharmova Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Jubilant Pharmova's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530019 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jubilant Pharmova (BOM:530019) has a Receivables Turnover of 2.08 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Jubilant Pharmova and its competitors. According to the industry distribution chart, Jubilant Pharmova ranks #172 out of 947 companies in the Drug Manufacturers industry, placing it in the top 18.2%.
Is Jubilant Pharmova's Receivables Turnover too high?
Jubilant Pharmova's current Receivables Turnover is 2.08. The Drug Manufacturers industry median Receivables Turnover is 5.08. Jubilant Pharmova's value of 2.08 is 59.1% below this industry median. Based on the distribution chart, Jubilant Pharmova ranks #172 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jubilant Pharmova has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #172 out of 947 companies for Receivables Turnover. This places Jubilant Pharmova in the top 18% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.08. Jubilant Pharmova's value of 2.08 is 59.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jubilant Pharmova's current Receivables Turnover of 2.08 is 59.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Jubilant Pharmova and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Pharmova's current Receivables Turnover is 2.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,090.12, compared to a current price of ₹906.35 — trading 16.9% below its estimated fair value. The current Receivables Turnover is 2.08 and 59.1% below the Drug Manufacturers industry median of 5.08. Jubilant Pharmova's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current Receivables Turnover is 2.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹906.35 is trading 16.9% below its estimated GF Value™ of ₹1,090.12.
GuruFocus considers Jubilant Pharmova to be Modestly Undervalued.
Key valuation signals for BOM:530019:
Receivables Turnover: 2.08
GF Value™: ₹1,090.12 vs. price of ₹906.35 (16.9% below fair value)
Industry Position: 59.1% below the Drug Manufacturers median (#172 of 947)
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
71GF Score
Get the complete analysis for BOM:530019
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
